To investigate the expression and clinical significance of Bridging INtegrator 1 () and cyclin D2 () in newly diagnosed cytogenetically heterogenous adult acute myeloid leukemia patients. Real-time quantitative PCR (RQ-PCR) was used to detect the expression of and genes in 49 newly diagnosed adult patients with AML, and their clinical significance was analyzed. and genes are highly expressed in patients with AML, which suggest their potential as molecular markers. A statistical significant correlation was found between expression with bone marrow blasts ( = 0.012), CD34 expression ( = 0.026), NLR ( = 0.019) and Karyotype risk ( = 0.005). There was a statistically significant correlation between and age ( = 0.001), NLR ( = 0.046) Karyotype risk ( = 0.033). The expression level of was related to early treatment response (CR or not) ( = 0.043). expression was significantly correlated with overall survival ( = 0.013), but not with CR ( = 0.731). and genes are highly expressed in patients with AML, suggesting the potential of these two genes as molecular markers. Moreover, high levels of are associated with better prognosis, suggesting the possibility of these two genes as prognostic markers.